Ethinylestradiol
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
| |
| Ethinylestradiol
| |
| Systematic (IUPAC) name | |
| 17-ethynyl-13-methyl- 7,8,9,11,12,13,14,15,16,17- decahydro-6H-cyclopenta[a] phenanthrene-
3,17-diol | |
| Identifiers | |
| CAS number | |
| ATC code | G03 L02AA03 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C20H24O2 |
| Mol. mass | 296.403 |
| Pharmacokinetic data | |
| Bioavailability | 97% is bound |
| Metabolism | Liver |
| Half life | 36±13 hours |
| Excretion | Urine |
| Therapeutic considerations | |
| Pregnancy cat. |
X (USA) |
| Legal status |
Rx-only (U.S.) |
| Routes | Oral, transdermal |
|
WikiDoc Resources for Ethinylestradiol | |
|
Articles | |
|---|---|
|
Most recent articles on Ethinylestradiol Most cited articles on Ethinylestradiol | |
|
Media | |
|
Powerpoint slides on Ethinylestradiol | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Ethinylestradiol at Clinical Trials.gov Trial results on Ethinylestradiol Clinical Trials on Ethinylestradiol at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Ethinylestradiol NICE Guidance on Ethinylestradiol
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Ethinylestradiol Discussion groups on Ethinylestradiol Patient Handouts on Ethinylestradiol Directions to Hospitals Treating Ethinylestradiol Risk calculators and risk factors for Ethinylestradiol
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Ethinylestradiol | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Ethinylestradiol, also ethinyl estradiol (EE), is a synthetic derivative of estradiol. Ethinyl estradiol is orally bio-active and the estrogen in almost all modern formulations of combined oral contraceptive pills (the Pill). It is one of the most commonly used medications.
The first orally active synthetic steroidal estrogen, ethinylestradiol (17α-ethynylestradiol), the 17α-ethynyl analog of estradiol, was synthesized in 1938 by Hans Herloff Inhoffen and Walter Hohlweg at Schering AG in Berlin.[1][1][1][1][1]
Ethinylestradiol was approved by the FDA in the U.S. on June 25, 1943 and marketed by Schering as Estinyl.[1] The FDA withdrew approval of Estinyl effective June 4, 2004 at the request of Schering, who had discontinued marketing Estinyl.[1]
While estradiol is readily absorbed when taken orally, it is also quickly inactivated by the liver. Substitution at C17 of the estrane steroid with an ethinyl group proved to provide an estrogen that is much more resistant to degradation and paved the way for the development of oral contraceptives.
EE is absorbed in the small intestine and reaches a serum peak about 2 hours later. It undergoes extensive metabolism in the liver involving the cytochrome P450 3A4 isoenzyme. EE and its metabolites are in excreted with the bile. Due to the effect of enterohepatic circulation as second peak is seen several hours later. Individually, wide variations exist in the overall absorption process, and can be further modified by drug (i.e. antibiotics) that affect the enterohepatic circulation or liver enzymes. In circulation EE is almost fully bound to plasma albumin. It is metabolized by hydroxylation of the aromatic ring and excreted in both, feces and urine, in part as glucuronide and sulfate conjugate.
EE is hormonally effective by activating the estrogen receptor and thus used as an estrogen. It finds its most common use in the estrogen-progestin combination preparations of oral contraceptives. Over time, formulations have decreased the EE dose from as high as 100 μg to as low as 20 μg.
All the contraindication and precautions apply for EE as with other estrogen medications.
Estinyl was a preparation of EE alone that was used for the management of menopausal symptoms and female hypogonadism.[1]
EE is released into the environment as a xenoestrogen.
See also
References
External links
da:EthinyløstradiolAcknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
